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Abstract: Oncoproteomics is nothing but the analysis of proteins and their interactions in a cancer cell 
through proteomic technologies. Oncoproteomics is playing a progressively significant part in diagnosis 
and the management of cancer. It also helps in the advancement of personalized therapy of cancer. 
Oncoproteomics holds great potential not only for opening the complicated molecular episodes of 
tumorigenesis but also for those that regulate clinically essential tumor habits, like metastasis, invasion, 
and resistance to treatment. Protein molecules show a significant impact on the evolution of cancer as it 
mainly develops due to abnormal signaling pathways. Detection and comprehension of these alterations 
is the major concept of oncoproteomics. Novel proteomic technologies related to cancer are defined in 
short, which are assisting not only in the comprehension of the mechanism of drug-resistant in cancer 
but also bestow some guides in management. For the diagnostic and prognostic categorization of the 
disease condition, and in measuring the drug efficiency and toxicity acclimatization of proteomic 
technologies in clinical laboratories is the fundamental objective of oncoproteomics. A considerable 
influence on the management of cancer patients and on a spectacular revolution in cancer research might 
notice by data obtained through such novel technologies. For the cancer therapy, the identification of 
novel targets, as well as an understanding of tumor development, might permit by the research of 
tumor-specific proteomic profiles. A wide perspective on drug-resistant and anticancer drug discovery, 
proteomic biomarkers and its function in the diagnosis of cancer, current innovation in proteomic 
technologies have tried to give in this review. 
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1. Introduction 
In current days, the human race is disturbed by one of the most considerable universal health 
apprehension symbolized by cancer. With the increasing growth and aging of the world’s residents, the 
overall load of the cancer is predicted to rise and globally the condition is set to worsen because cancer 
not only disturb the developing nation but also developed nation [1]. With cancer, more than 11 million 
individuals are detected every single year. As per the prediction, every year there will be 16 million fresh 
cases by 2020. In worldwide mortality, cancer contributed 7.6 million (or 13%) in 2005, from a total of 
50 million demises universally. Loss due to cancer in the universe is estimated to continue growing, as 
per prediction in 2015 due to cancer 9 million individuals died and 11.4 million human being will die in 
2030 [2-3].  
 A few years ago the extent of complexity of the illness which was not evident, has been 
exposed due to the increase in basic knowledge about cancer. For instance, for given cancer categories 
(e.g. leukemia and breast) the figure of molecular subtypes identified is increasing rapidly, in terms of 
not only the cell type but also the differentiation status and its interaction with tumor microenvironment 
the daunting heterogeneity of tumor cells is not yet fully understood, and application as well as 
evaluation of novelties as well as in the clinical supervision of cancer victims the ever-increasing need 
for multidisciplinary has become the more complex. A successfully increase in cure rates, may only be 
accomplished by combined collaborative activities focused on enhancing therapeutic strategies and 
prevention which helps in a noteworthy relief of the cancer load, in the short-range. If malignity is 
identified in advance i.e. when they are confined to a minor area and are still small, cancer can be 
managed more successfully and with fewer morbidity for victims as well as a key link between 
treatment and prevention is expected to be provided via advance diagnosis. 
 Novel biomarkers as well as targets for drug discovery, will be recognized as our awareness of 
the biology concealed in the malady pathogenesis improves, specifically with the signaling mechanism 
which are disturbed in tumor cells and “the right drug for the right patient at the right time” i.e. the 
personalized cancer treatment, are expected to be results from these innovative molecular targeted 
treatments. In this manner, to impart functional insight for generating innovative targets for drug 
development and companion diagnostics, and to characterize as well as define functional and regulatory 
networks proteomic technologies are estimated to perform an important character because they offer 
crucial measures [4]. 
2. An outline of proteomic technologies in Cancer Research 
Molecular modifications which take place in a cancerous cell can be noticed as biochemical alterations 
demonstrated on a protein level. More than 20,000 proteins are assessed to be involved in the human 
proteome. A plethora of vital mechanisms involved in functionality as well as cell signaling can be 
exposed by the reviewing proteins that are differentially expressed in cancer cells. In cancer research, 
there has been a noteworthy rise in proteomics-based research, particularly, within the last 20 years. The 
applied proteomic research application dates back to the early 2000s [5-6]. The reorganization of 
abnormal as well as inadequate proteins in exceptional materials is possible because of a number of 
growing scientific progress which has increased our understanding of oncoproteomics [7-9]. In cancer 
research, proteomic approaches are progressively being used as a result of data management, 
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better-quality equipment, and computer algorithms in combination with the integrative understanding of 
oncogenic signaling pathways [10-14].  
 The original version of the study of cancer built on protein identification has changed to 
protein functional analysis because of the complexity of cancer [15]. Because of this, the cancer research 
has transformed to the comprehension of complicated oncogenic signaling route which was formerly 
based on the discovery of a single cancer biomarker [16-17]. The measurement of specific proteins in 
samples with high assurance, the identification of post-translational protein alterations (e.g., 
phosphorylation, glycosylation, as well as oxidation) and the study of protein-protein interactions, are 
facilitated by strong and potent techniques presently used in proteomic research. For this objective, 
evolving analytical approaches comprise nanoproteomics, tissue microarray, cancer immunomics to 
identify autoantibody signatures, aptamer-based molecular probes, and antibody microarray. 
 
2.1 Nanoproteomics 
 
In the advances of oncology, an important role has been played by nano-oncology, which is the 
application of Nanobiotechnology to cancer [18]. The early diagnosis of cancer and the discovery of 
biomarkers of cancer is enabled by molecular diagnostics and proteomics which is refined by 
nanobiotechnology. For various technical challenges in proteomics as well as molecular diagnostics 
based on protein, a solution was provided by the nanomaterials [19]. In proteomics, by the use of 
nanoscale devices such as nanofluidics and nanoarrays, the improvement in the oncoproteomics study 
has been seen. The nanoscale analysis is subjected to low abundant proteins as well as those proteins that 
are extracted from limited source materials for e.g. biopsies. Mass analysis of peptide fragments leads 
by the nano-capture of particular proteins as well as complexes, and development of entire subsequent 
specimen handling stages, with single protein reorganization accuracy at the low zeptomole level. This 
is a much-focused method and also called as targeted proteomics, which includes the inspection of 
subsections of the proteome for e.g. the proteins which exist as a member of higher order complexes or 
those proteins that are either characteristically altered, or fix to a specific DNA structure, or a 
combination of thereof. To recognize how cancer genetics determinants modify cellular physiology as 
well as respond to agonist’s, nanoproteomics can be used, which will help in cancer for the development 
of personalized therapy. 
 
2.2 Tissue microarray 
 
In oncology, for the analysis of molecular biomarkers, a tissue microarray (TMA) is a high productivity 
tool. In a single microscopic slide analysis of up to 1000 tissue samples is enabled by the tissue 
microarray. For the detection of cancer biomarkers, development of diagnostic tests and for the study of 
tumor biology TMAs are very useful [20]. Laser capture microdissection can be combined with tissue 
proteomics. For oncoproteomics TMAs are a useful tool. From formalin-fixed paraffin-embedded 
prostate cancer tissue samples, to identify proteins without deviation direct tissue proteomics can be 
used [21]. For testing of breast carcinoma for human epidermal growth factor receptor 2 (HER2) status, 
and to compare favorably with fluorescent in situ hybridization and with immunohistochemical, TMA 
technology has been applied [22]. 
 
2.3 Role of cancer immunomics in identifying autoantibody signatures 
 
In cancer, the increased incidence of autoantibodies is well known. In the presence of either breast or 
colorectal cancer as a response autoantibody signatures are produced and cancer immunomics has been 
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used to identify it. Immunoblotting, image analysis, 2D GE and MS are used to perform serological 
proteome analysis (SERPA) [23]. An approach has been developed that combines, Nan flow separation 
of the resulting peptides, and identification, enzymatic digestion of the isolated antigens, 2D 
immune-affinity chromatography, MAPPing (multiple affinity protein profiling), as an alternative to 
identifying the antigens recognized by the autoantibodies of the cancer patients. A limited number of 
proteins reacting preferentially with cancer sera as well as proteins recognized by autoantibodies 
independently of a cancer status are identified by these approaches. 
 
2.4 cancer proteins and function of aptamer-based molecular probes 
 
Due to the particular 3D structure of aptamer-based molecular probes, they can bind to a given ligand 
with a high specificity and affinity by which the biological function of ligand gets antagonized. To 
detect protein signatures of the cells aptamers are used, because of the tendency of short DNA to fold 
into shapes that bind to specific proteins. The technology can be combined with biochips which will give 
a method for monitoring protein changes in the blood as an indication of the development of 
carcinogenesis, for example in women with genetic risk of breast cancer associated with BRCA1 
dysfunction. 
 For T-cell acute lymphoblastic leukemia, as a biomarker protein tyrosine kinase 7 (PTK7), has 
identified, which is enabled by the use of a two-step strategy, aptamer selection and biomarker discovery, 
combined with mass spectrometry [24]. The cell-SELEX (systematic evolution of ligands by 
exponential enrichment) process is used for selection of aptamers for leukemia cells, without any prior 
knowledge of cell biomarker population, conjugated with magnetic beads and then used to capture and 
purify their binding targets on the leukemia cell surface. The significant enhancement within the 
effectiveness of biomarker discovery and the therapeutic approaches to cancer as well as the 
development of diagnostic tools will be facilitated by this two-step strategy.  
 
2.5 Antibody microarray 
 
Due to the recent advances in proteomics and automation, the use of antibody microarray continues to 
grow rapidly, and opportunely a high-throughput multiplexed analysis of protein biomarkers is created 
by this combination. Simultaneous measurement in a single sample of many proteins that work in 
pathways and a network of cancer has enabled by the antibody arrays [25]. However, for protein, the 
lack of PCR like amplification methods is a primary limitation of this technology. To quantify protein 
biomarkers in the femtomolar range, and from limited sample quantities with very high sensitivity, it is 
necessary to construct assay, to realize the full potential of array-based protein biomarker screening. 
Combining the advantages of a microarray including the ability to screen very small sample volume, 
cost saving and higher throughput, and multiplexing capabilities the construction of ultra-microarray 
has been described by the Scientist at BioForce Nanoscience Inc. [26]. For prostate cancer screening, 
widely used biomarkers such as IL-6 and PSA were constructed by the antibodies ultra-microarrays. 
With the detection level in the attomole range using purified proteins, these ultra-microarrays were 
found to have a high sensitivity and specificity. 
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3. The function of proteomics in cancers of varies organs 
With suitable cases of breast, prostate and lung cancer as well as in leukemia and colorectal cancer the 
function of proteomics not only in the development of personalized approaches but also in therapy, 
diagnosis as well as in the combination of both has been described. 
 
3.1 Breast cancer and proteomics 
 
The human epidermal growth factor receptor-2 (HER-2) gene, in the management of breast cancer 
which is enlarged by 20-30%, is a model of association of therapeutics as well as diagnostics. HER2 lack 
is related with resistance to therapy, however, its overexpression is linked with respond to Herceptin 
(Genentech). Fluorescents in situ hybridization (FISH) and immunohistochemistry (IHC) are two ways 
to determine the HER-2/neu state of primary breast cancer. Patients having breast cancer whose tumor 
tissue represents the HER2 protein, is identified by an approved IHC test which is HercepTest 
(DakoCytomation). Interphase HER2/neu gene intensification, is quantitatively determined by HER2 
FISH pharmDxTM kit. Improved clinical acceptance to an anthracycline-containing chemotherapy 
regimen, as compared to the treatment with methotrexate, fluorouracil, and cyclophosphamide when 
subjected to the intensification of HER2 in breast cancer cell is shown by the National Cancer Institute 
of Canada by Mammary5 trial [27]. 
 Nevertheless, because of some technical issues, tests applied in initial phase breast cancer 
might not precisely reflect in metastatic tumor with regards to HER-2/neu status. If 30% or more of the 
cells are 3+, then tumors should be designated as HER-2/neu positive as suggested by the guidelines. 
With the aid of authenticated test, in serum, the circulating levels of the HER-2 extracellular domain can 
be determined and above 15 ng/ml, increased level of serum HER-2/neu displays advancement in breast 
cancer [28]. 
 
3.2 Prostate cancer and proteomics 
 
Biomarkers for the identifying, checking as well as characterizing the signaling phenomenon inside the 
actual human biopsies will be critical for patient-tailored treatment with the advent of molecular 
targeted therapeutics. The most powerful method which might expose the regulation of gene that can’t 
be identified on a genetic level as well as for the analysis of cellular protein phenotype, 2D gel 
electrophoresis remains the most potent technique, although several non-2D gel electrophoresis 
technologies are available for study in prostate cancer proteomics.  
 A prostate-specific antigen (PSA) which is an androgen-regulated gene, as well as numerous 
innovative complementary DNAs, has been displayed by the prostate cancer gene expression researches. 
2D gel electrophoresis has generated profiles of protein expression belonging to androgen-stimulated 
cells of prostate cancer. On human prostate tissue cells, the assessment of the number of PSA 
molecules/cells has been performed by linking LCM with sensitive quantitative chemiluminescent 
immunoassay. Alterations in expression of PRDX4, FKBP4 as well as FLNA (7-15) have been 
established through immunoblot analyses, in addition for generating an extra intact outline of prostate 
needle biopsy specimens a method build on proteomics is applicable [29]. For treatment and diagnosis 
of prostate cancer, the useful molecular target is provided by this approaches. 
 
3.3 Lung cancer and proteomics 
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Presently, for accomplishing the objectives of determining a therapy and assessing prognosis, the 
pathological, as well as the clinical staging of lung cancer, is unsatisfactory. Because of the technical 
advancements within proteomic as well as genomic analyses, in addition to their implementation in the 
prognosis and diagnosis of cancer of lung, crucial developments in comprehension of the molecular 
basis of lung cancer has been created. A straightforward as well as noninvasive technique, which is 
exhaled breath condensate collection, by sampling respiratory track fluid it assists the study of numerous 
biomarkers comprising proteins and may be applicable in finding of lung cancer [30]. For diagnosing 
the persons at the great possibility for lung cancer and also in suggesting the diagnosis for same, a group 
of four serum proteins (squamous cell carcinoma antigen, alpha 1-antitrypsin, retinol binding protein, 
and carcinoembryonic antigen) are appreciated [31]. Potential therapeutic targets can be provided 
through if a trustworthy protein profile is recognized that is linked to inferior detection. To enable a 
personalized treatment, before the clinical manifestation of lung cancer for its diagnosis the evolvement 
of straightforward serum test is practicable which may also concurrently detects the chemotherapeutic 
drugs to which the tumor is susceptible [32]. Prior to the implementation on advancement in the 
management of patients with lung cancer which can be evaluated adequately, there is a necessity for 
transforming the technology from bench to the besides as well as additional developments in sample 
preparation methods. 
 
3.4 Leukemia and proteomics 
 
Because, the cytogenetic analysis is time-consuming and it is expensive, to subclassify leukemia 
proteomics is being used. To rapidly identify different type of leukemia several useful protein 
biomarkers have been discovered: annexin 1, tropomyosin 3, peroxiredoxin 2, catalase, annexin A10, 
RhoGDI 2, alpha-enolase. For disease prognosis as well as an outcome they can be used as biomarkers 
which are differentially manifested in acute myeloid leukemia (AML) [33]. For treatment of AML based 
on rational pathogenesis, they offer potent novel targets.  
 In AML, the total survival of patients remains disappointing regardless of massive therapeutic 
attempts which range from allogeneic stem cell transplantation to numerous cytotoxic agents. In AML, 
the discovery of novel biomarkers, as well as therapeutics, will be developed by the interpretation of the 
AML- specific proteome which also assists in the evolution of personalized management. Limitations in 
protein detection sensitivity are one of the major challenges, as several regulatory proteins that are 
essential in response to treatment found in a small amount, which represent a challenge [34]. The 
opening of new avenues for personalized molecular therapy for AML as well as improvement in 
efficacy and reduction in toxicity of present therapy are expected to happen due to ongoing 
developments in proteomic technologies. 
 
3.5 Colorectal cancer and proteomics 
 
A maximum number of the carcinomas of the colon is still identified at a far ahead phase when 
prognosis is reduced, despite colonoscopy and fecal occult blood test which are existing screening 
method for colorectal cancer (CRC) which have contributed a reduction of mortality and early detection. 
With high specificity and sensitivity, a dissimilarity between the cancer patient and healthy patient is 
enabled by the proteomic technologies, which could also greatly improve the classification systems for 
CRC as well as its early detection [35]. Utilizing SELDI-TOF MS followed by a classification of three 
pattern analysis of CRC by a serum protein profiling appropriate technique for identifying novel serum 
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biomarkers has been defined [36]. In supervising the disease and the therapy these biomarkers play the 
crucial character.  With the optimum goal of tailoring treatment to a tumor profile and to an individual 
patient as well as to decrease toxicity and improve response rate, there is still a necessity to recognize a 
panel of predictive markers. From the bench to the bedside the application of proteomic skills for CRC is 
yet to be transmitted.  
 The most general phenomenon and the main harmful reason of the CRC is the metastasis. 2D 
GE joined with matrix-assisted-laser-desorption/time of flight (MALDI TOF) MS was used to 
conducted differential proteome analysis of two CRC cell lines [37]. With varying potential for 
metastasis, obvious changes were sensed between the protein profiles of colorectal cell lines. In 
progression and metastasis of CRC, an important role was shown to be played by the overexpression of 
heat shock protein (HSP) 27. 
4. The function of proteomics in drug discovery of cancer 
In traditional drug discovery to rectify some of the scarcities, proteomic technologies are being utilized 
as an effort. In malignancy, as there are deficiencies in the protein machinery of the cell, that’s why 
proteins become the vital targets for drug discovery, predominantly in cancer. To estimate the effect of a 
candidate drug on disease state, proteome investigation can be utilized because it can yield a widespread 
molecular profile of the difference among diseased as well as the normal state. In oncology, for target 
validation and drug discovery, oncoproteomics incorporated with oncogenomics is the latest tendency 
[38]. Selection of the finest candidate among novel drug targets, as well as the estimation of all probable 
protein coding region, has been allowed by the use of proteomics technologies. The anticancer drug 
target discovery, as well as its validation, has been possible through the identification of modifications 
definite to the tumor [39]. The prediction of response of the individual patient, identification of disease 
subgroup, assessment of toxicity and efficacy of the candidate drug as well as the target discovery, all 
these contributions are made by the human saliva proteomics which might be beneficial for anticancer 
drug finding [40].  
 The development of breast cancer which points out by the intercellular signaling pathway, 
whose study has been assisted by the functional proteomics, will function as a leader for the growth of 
anticancer drugs. To understand the part of the breast cancer proteome, there is a requirement for 
innovative technologies for e.g. protein microarray, because with 2-D gel electrophoresis it is unable to 
reveal it [41]. Within body fluids for quantification of carcinogenic embryonic antigen (a single protein) 
and for a finding of colorectal, a classic test is founded on proteomics. For prediction of the treatment 
and disease outcome there is a necessity for supplementary research on genotype-phenotype 
relationships. To define cell dysfunction in carcinogenesis which is generally not resulted in multiple 
characters is possible through researches by applying specific tools such as tagged antibodies [42]. In 
colorectal cancer, there is a need for further development of studies linking large protein expression 
patterns with the clinical outcome which are still in their infancy. A profile of protein produced by a 
mass spectrometry and investigated through an artificial intelligence-based algorithm to discover the 
hidden patterns of combinations of markers which can differentiate cancer victims from healthy once 
[43]. The implementation of the proteomics methodology, which is created by high-resolution 2-D gel 
electrophoresis combined with multivariate correspondence analysis as well as mass spectrometry, is 
used to categorize accurately the biochemical basis of the anti-cancer action of the synthetic 
cyclin-dependent kinase inhibitor, bohemine, [44]. An advanced resistance of A549 lung carcinoma 
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cells to bohemine compared to the CEM leukemia cell line is corresponded to the alterations in the 
protein expression patterns.  
 3D protein structure determination, laser capture microdissection, protein biochips, as well as 
protein-protein and protein-drug interaction, these are the most important proteomics technologies 
accessible for anticancer drug discovery. The important drug targets involved in malignancy are cancer 
biomarkers and signaling pathways. For developing novel therapeutic agents for cancer, the unlimited 
possibilities are provided by the wealth of new knowledge in the proteomic database together with 
bioinformatics as well as a microarray. 
5. Proteomics and drug-resistant cancer 
Development of resistance to the anticancer drugs in the chemotherapy of cancer is one of the serious 
trouble. Cross-resistance with a large number of alternative medicines results from treatment with one 
anticancer drug, in multiple drug resistant (MDR). P-glycoprotein, which is plasma transport protein, is 
regularly expressed by these MRD cells. A biochemical mechanism such as DNA replication, and repair 
mechanism or cellular drug transport and detoxification, as well as proliferation status and cell cycle 
stage, might affect cellular resistance to chemotherapy which is multifactorial. For the reorganization of 
not only MDR markers but also mechanism, a number of laboratory practices are utilized for an instance 
polymerase chain reaction, immunocytochemistry, flow cytometry, blotting, and fluorescent 
microscopy. 
 In drug-resistant cancer, the involvement of multiple proteins identification has been 
facilitated by the developments in proteomic technologies. The recognition of differentially expressed 
proteins among the cells of resistant versus sensitive has been possible by 2D GE, following image 
analysis as well as MS. When proteins unsuitable expression or structure is responsible for the 
drug-resistant disease, this may results into advancement in various techniques which will transform the 
action of such proteins. 
 In patients with lung cancer, a clinical co-relation to objective response to gefitinib has been 
recognized as the mutations in epithelial growth factor receptor (EGFR), however, it does not point out 
resistant to gefitinib. An acquisition of gefitinib resistance has been correlated by the expression of a 
surface biomarker such as epithelial membrane protein-1, an adhesion molecule. The common 
mechanism of resistance nominated in a spectrum of cancer cell line, from the various mechanisms of 
resistance likely present in any given drug-selected cancer cell line have been uncovered by the 
combined analysis of multiple proteomic types of research of varies drug-resistant cancer cell lines [45]. 
In the future to get rid of cancer, combination treatments targeting multiple mechanisms to sensitize 
drug-resistant cancer might be significant, as recommended by this observation. 
6. The function of proteomics in molecular diagnosis of cancer 
For the detection of cancer, as a fundamental addition over the antibody-based technique as well as 
genomic, proteomic technologies have emerged. The detection of biomarkers for cancer as well as 
protein pattern study is the foundation of many of these assay. For the development of individualized 
therapy of cancer, a significant role has been performed by the nanotechnology through the 
incorporation of diagnostics with therapeutics, which also permit additional improvements of these tests. 
For identifying tumor-specific changes in proteins, proteomic separation, as well as analytical practices, 
have unique capabilities. For the detection of cancer in advance, proteomic techniques have the ability to 
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identifying molecular markers and diagnostics. During the next decade, these findings will modify the 
current grading methods and pathological classifications for cancer [46]. The humoral response which is 
elicited by the tumor-associated antigens whose identification is enabled by the proteomics [47]. From 
several types of cancer, within the sera, high-frequency antibodies revealed by a proteomic-based 
approach. Within the clinical application, in determining prognosis as well as in diagnosis and as a novel 
biomarkers this antigenic protein might work. 
 
6.1 Proteomic analysis of cancer cell mitochondria 
 
In cancer cells, a mutation in mitochondrial DNA has been regularly detected. Until now, the 
importance of the pattern of gene expression has not been acknowledged. Our knowledge about cancer 
through research on mitochondrial proteome can be advanced by: 
 
 In cancer cells, detection of atypically expressed mitochondrial proteins is enabled with the help 
of mitochondrial functional proteomics. 
 Targets for therapeutic inventions, as well as for risk assessment and early detection of new 
biomarkers can be discovered through proteomics. 
 
In gastric cancer cell line of human, increased manifestation of four mitochondrial proteins such as 
mitochondrial elongation factor Tu, heat shock protein 60, mitochondrial short-chain enoyl-coenzyme 
A hydratase-1, and ubiquinol-cytochrome c reductase has been revealed by the inspection of the 
mitochondria enhanced fraction by 2D gel electrophoresis [48]. At the protein level the procedure of 
mitochondrial alterations in cancer is provided by these findings and in mitochondria, it may function as 
active cancer biomarkers. 
 
6.2 Diagnosis of cancer by protein pattern 
 
For diagnosis of different cancer the application of proteomic biomarkers is well recognized and as 
compare to single biomarker protein pattern offer better diagnostic possibilities. Free from the identity 
of peptides and proteins, the pattern itself is the discriminator as per this approach, and it might also 
represent a novel diagnostic paradigm. The foundation of pattern determination is the application of 
machine learning technologies for e.g. neural networks, decision trees as well as different algorithms. 
The signaling pathways of cancer are known to be managed by post-translational protein alteration, 
which can be identified with great assurance by the application of high-resolution MS. For comparison 
of peak pair with a traditional peak pair technique, a model was built from data produced by the use of 
prOTOF MS on samples from patients with ovarian cancer as well as from cutaneous T-cell lymphoma 
[49]. The peak pair gave classification equal to superior as compared to a traditional technique that used 
multiple individual peaks, as shown by the results and in disease process for recognizing of fundamental 
peak pairs it can be used. 
 In ovarian cancer for detection of its early stage proteomic profiling has potential. A clear 
intensification of the sensitivity resulted from combining the CA125 with the recently revealed 
biomarkers of ovarian cancer progression and in the large control group and ovarian cancer, it should be 
validated [50]. For ovarian cancer screening as well as for malady monitoring during and after therapy 
such a multi-marker assay could be suitable. 
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6.3 Early detection of cancer through serum proteome analysis 
 
The advance diagnosis of cancer is permitted by the identification of biomarker patterns or the new 
biomarkers through the application of proteome analysis. In serum or other body fluids, the 
reorganization of secretory products derived from the tumor is allowed through this tool. Besides, in the 
serum of cancer patients, it might be used to determine the decreased level or loss of proteins, which are 
usually present in non-cancer patients. Immunological alterations or cancer-specific metabolite are 
responsible for these changes in serum proteome, which are, at least partially, free of tumor size or mass, 
and by this means enabling advance diagnosis [51]. 
 In plasma, an increased amount of angiogenic regulatory proteins e.g. endostatin and VEGF 
are shown by the SELDI-TOF-MS of platelet essence for proteomic profiling but these are absent in 
plasma. It is not a straightforward relationship with the platelets surface instead it is a selective 
sequestration method. In human, microscopic size cancer can be detected by this novel property of 
platelets which is not possible by any presently available diagnostic methods. A detection of a wide 
range of tumor size as well as tumor type is enabled by this and instead of a single biomarker, it is more 
inclusive. The tumor movement from its initial in-situ stage throughout its development is allowed by 
the corresponding modification in the platelets angiogenic profile. 
 
6.4 HER-2/neu oncoprotein as a biomarker for cancer 
 
In the progression as well as in the development of breast cancer an essential part is played by the 
HER-2/neu oncoprotein which has been revealed by the extensive study for many years. In patients, 
demonstrating aggressive disease, a high possibility of relapse of malady as well as overall reduced 
survival, HER-2/neu were displayed as a sign of poor prognosis. In around 30% of a female having 
breast cancer, a high level of HER-2/neu is found, which is supported by many published studies. In 
identifying whether that patient has a serious aggressive disease and would, thus, derive substantial 
profits through additional intensive treatment regimens, determination of patient’s HER-2/neu status 
may be valuable. Besides breast cancer, in numerous other tumor forms such as lung, prostate, 
pancreatic, colon, as well as ovarian cancers high levels of HER-2/neu are found.  
 Females displaying recurrent, metastatic breast cancer, the information regarding the 
HER-2/neu status are not provided by the conventional HER-2/neu testing which is normally restricted 
to the tissue sample obtained by primary breast cancer. Over the course of the disease, existing 
estimation of a woman’s HER-2/neu status is provided by a less invasive diagnostic tools microtiter 
plate ELISA HER-2/neu testing with the help of the serum sample. For breast cancer, the result of 
chemotherapy settled on neoadjuvant anthracycline is significantly predicted by the pre-chemotherapy 
serum HER-2/neu [52]. 
7. Diagnostic biomarkers 
For the detection of syndromes, the implementation of proteomic technologies is called diagnostic 
oncoproteomics. Within the significant decrease in a fatality, the advance diagnosis of cancer has a 
principal role. From victims displaying breast, uterus and ovarian cancer as well as the victims with a 
benign ovarian tumor, the serum specimen thermo stable fractions has been examined with the help of 
two-dimensional gel electrophoresis (2-DE) accompanied by matrix-assisted laser desorption/ionization 
time-of-flight (MALDI-TOF)/TOF MS. In results, the ovarian cancer sample showed a reduction in 
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transthyretin, while in breast cancer the clusterin, as well as alpha-1-acid glycoprotein, has been 
precisely down-regulated. Within numerous tumor, the haptoglobin alpha1 was raised, whereas a 
decreased spot volume was seen with apolipoprotein A-I forms. For small as well as medium protein 
examination, as a favorable weapon thermostable fraction of serum might be suggested, especially 
through 2-DE [53]. 
8. Proteomics biomarkers in cancer 
The incomplete understanding of oncogenesis and etiology, as well as the lack of a definite warning sign 
in early disease, makes the advance diagnosis of cancer challenges. For instance, the less sensitivity of 
blood tumor marker i.e. cancer antigen (CA) 15-3 for breast cancer makes it unusable for early 
recognition. For this reason in some nations, for the breast cancer diagnosis, the measurement of HER-2 
and carcinoembryonic antigen (CEA) in unusual nipple secretion has been sanctioned [54]. As a 
response to a therapeutic intervention as well as a signal to the pathological process, the biomarkers can 
be evaluated as well as objectively measured. Whichever measurable definite molecular changes of 
cancer cell either on metabolite or protein level, RNA or DNA, is defined as a cancer biomarkers [55]. 
The dramatic decrease in death is possible by the potential of early diagnosis of cancer. The targets for 
drug discovery as well as numerous molecular diagnostics of cancer has founded on the biomarkers. The 
prediction and observing the response to the treatment, determining prognosis, as well as the 
classification of tumors, is enabled by the fundamental scientific application of cancer biomarkers. 
Within the tissue, the expression of a definite gene will permit its reorganization accompanied by none 
of the neighboring cell representing a certain marker. Within last few decades, as per the tumor subtype, 
a comprehensive classification has been enabled through cancer cells molecular dissection by virtue of 
profiling of mRNA expression. In table no. 1 the comparison of present tumor marker as well as 
proteomic biomarkers with their sensitivity and specificity are listed.  
 
Table 1 Difference between the present day tumor markers and proteomic biomarkers 
 
Cancer 
type 
Present tumor markers Proteomic biomarkers 
Markers Specificity Sensitivity Specificity Sensitivity Reference 
Prostate PSA (Prostate Specific Antigen) 20-34% 86% 97% 83% 56 
Ovarian CA-125 (Cancer Antigen-125) *** 57% 94% 83% 57 
Liver AFP (Alpha-Fetoprotein) 90% 50% 86% 94% 58 
Colorectal CEA (Carcinoembryonic Antigen) *** 43% 93% 91% 59 
Bladder NMP22 (Matritech’s nuclear matrix 
protein) 
95% 31% 90-97% 80% 60 
Breast CA 15-3 (Cancer Antigen 15-39) 80-88% 63% 91% 93% 61 
Gastric CEA (Carcinoembryonic Antigen) *** 49% 95% 83% 62 
Lung Cyfra 21-1 (Cytokeratin fragment) 94% 63% 80% 87% 63 
Pancreatic CA19-9 (Cancer Antigen 19-9) *** 72% 97% 78% 64 
 
9. Oncoproteomics and its implementation in the personalized 
management of cancer  
Individualized medicine, for enhancing healthcare of people is emerging concept, which fundamentally 
means the prescription of not only definite therapeutics but also treatment appropriate for an individual 
genotype, which is supported by the different factors that impact response to the treatment as well as the 
disease outcome. The advancement in the individualized treatment of cancer is assisted by progress in 
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oncoproteomics [65]. The influence of proteomics on cancer will not be constrained to the recognition 
of advanced biomarkers for early diagnosis as well as novel targets. As per the molecular outline of the 
cancer cell, the proteomics skills will be utilized to design rational drug and thus the development of 
initialized cancer treatment is enabled. On the advancement of individualized treatment of cancer, 
Nano-biotechnology will have an impact on it. In table no. 2 [66] the example of proteomic technologies 
utilized for personalized cancer treatment are summarized. 
 
Table 2 Summary of proteomic technologies and its application in personalized cancer treatment 
 
Sr. 
no. 
Technologies Application 
1. Glycoproteomics: in the form of glycoprotein in 
the cell membrane the biochemical signature of 
cancer  
Molecular targets expressed in tumors for which 
targeted cancer therapy 
2. To recognize the targets antigen biochemical assay 
as well as proteomic techniques  
For cancer treatment founded on antibody 
3. Fingerprints of laser proteins or peptides founded 
on mass spectrometry  
Molecular classification of human tumor, 
proteomic outline 
4. Structure determination of protein kinase: in 
cancer important drug targets 
 
Individualized anticancer drugs screening 
5. A functional map of know cell-signaling networks 
delivered by reverse phase protein microarrays 
[67] 
 
For individualization of treatment, for a single 
patient gained directly through a cancer biopsy 
specimen correlation of pathways with clinical 
information as well as biological 
 
10. Challenges and Conclusion 
For the detection of cancer and its prognosis as well as for the guidance of anti-cancer therapy numerous 
proteomics based tests are expected to become accessible. With the usage of proteomics, there are still a 
lot of challenges associated with the discovery as well as validation of cancer biomarkers. By the use of 
proteomics, there is no definite cancer biomarker has been documented as well as validated, besides 
several latest and in process efforts made to detect cancer biomarkers [68-69]. Tumor heterogeneity, the 
nature of proteomic technology employed, the usage of poor principles for the design of sample 
collection and studies, as well as the absence of universally standardized proteomic platforms, might be 
the reasons for this failure [70]. In cancer biomarker studies, unquestionably the main challenges to be 
addressed are serum proteomics and tumor heterogeneity. In addition, noteworthy obstacles to their 
usage are low-throughput, the inadequate dynamic range, as well as the high cost of MS-based 
proteomics [71]. 
 Only a negligible quantity of valuable information has been taking out from proteomic studies, 
on the other hand, it has provided a great amount of information. The reorganization as well as 
validation of appropriate clinical cancer biomarkers, might results in the upcoming years by the 
utilization of bioinformatics and combined proteomic-based approaches. Large-scale illness screening 
is done by, a non-invasive option offered by means of highly sensitive technology through the initial 
screening of cancer samples, which can be validated by using antibody-based panels to identify possible 
markers for disease treatment, diagnosis as well as prognosis. For information translation and analysis, 
profound biochemical and biological information, as well as a powerful statistical parameter is essential. 
In cancer research to detect reliable biomarkers, bio-bank resources, proteomic-based technologies can 
be utilized together with developments in bioinformatics and data management systems. 
 
  
 
Ivy Union Publishing | http: //www.ivyunion.org            ISSN 2572-5750           January 22, 2019 | Volume 7 | Issue 1 
Nimbalkar CK. American Journals of Cancer Science 2019, 7:1-17                                     Page 13 of 17 
 
7 
6 
Acknowledgment  
The author has no financial involvement in any of the technology, products or companies mentioned in this 
publication. 
Funding 
No funding was received for this study. 
Conflict of interest  
The author has no conflict of interest. 
Ethical approval 
This article does not contain any studies with human participants or animals performed by any of the authors. 
Informed consent 
Statement of informed consent was not applicable since the manuscript does not contain any patient data. 
References 
1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, et al. Estimates of worldwide burden of cancer in 
2008: GLOBOCAN 2008. International journal of cancer. 2010, 127(12):2893-2917 
2. Cho WC. Proteomics–leading biological science in the 21st century. Sci J, 2004, 56:14-17 
3. Cho WCS. Research progress in SELDI-TOF MS and its clinical applications. Chinese Journal of 
Biotechnology, 2006, 22(6):871-877 
4. Ringborg U, Celis JE. United we stand. Public Service Review: European Union 20, 2010, 199-200 
5. Celis JE, & Gromov P. Proteomics in translational cancer research: toward an integrated 
approach. Cancer cell, 2003, 3(1):9-15 
6. Plebani M. Proteomics: the next revolution in laboratory medicine?. Clinica chimica acta, 
2005, 357(2):113-122 
7. Hanash SM, Pitteri SJ, & Faca VM. Mining the plasma proteome for cancer biomarkers. Nature, 
2008, 452(7187):571 
8. Böhm D, Keller K, Wehrwein N, Lebrecht A, Schmidt M, et al. Serum proteome profiling of 
primary breast cancer indicates a specific biomarker profile. Oncology reports, 2011, 
26(5):1051-1056 
9. Cawthorn TR, Moreno JC, Dharsee M, Tran-Thanh D, Ackloo S, et al. Proteomic analyses reveal 
high expression of decorin and endoplasmin (HSP90B1) are associated with breast cancer 
metastasis and decreased survival. PloS one, 2012, 7(2):e30992 
10. Dumont B, Castronovo V, Peulen O,  l tard N, Clézardin P, et al. Differential proteomic analysis 
of a human breast tumor and its matched bone metastasis identifies cell membrane and extracellular 
proteins associated with bone metastasis. Journal of proteome research, 2012, 11(4):2247-2260 
11. Gormley M, TchafaA, Meng R, Zhong Z, & Quong AA. Proteomic profiling of infiltrating ductal 
carcinoma reveals increased cellular interactions with tissue microenvironment. Journal of 
proteome research, 2012, 11(4), 2236-2246. 
  
 
Ivy Union Publishing | http: //www.ivyunion.org            ISSN 2572-5750           January 22, 2019 | Volume 7 | Issue 1 
Nimbalkar CK. American Journals of Cancer Science 2019, 7:1-17                                     Page 14 of 17 
 
7 
6 
12. Khamis ZI, Sahab ZJ, Byers SW, Sang QX. Novel stromal biomarkers in human breast cancer 
tissues provide evidence for the more malignant phenotype of estrogen receptor-negative tumors. 
BioMed Research International. J Biomed Biotechnol. 2011, 2011:723650 
13. Li CI. Discovery and validation of breast cancer early detection biomarkers in preclinical 
samples. Hormones and Cancer. 2011, 2(2):125-131 
14. Riley CP, Zhang X, Nakshatri H, Schneider B, Regnier FE, Adamec J, & Buck CA large, consistent 
plasma proteomics data set from prospectively collected breast cancer patient and healthy volunteer 
samples. Journal of translational medicine. 2011, 9(1):80 
15. Aebersold R, Mann M. Mass spectrometry-based proteomics. Nature. 2003, 422(6928):198 
16. Sanchez A, & Villanueva J. PI3K-based molecular signatures link high PI3K pathway activity with 
low ER levels in ER+ breast cancer. Expert review of proteomics, 2010, 7(6):819-821 
17. Roukos DH. Disrupting cancer cells’ biocircuits with interactome-based drugs: is 
‘clinical’innovation realistic?. Expert review of proteomics, 2012, 9(4):349-353 
18. Jain KK. Recent advances in nanooncology. Technology in cancer research & treatment, 2008, 
7(1):1-13 
19. Johnson CJ, Zhukovsky N, Cass AE, & Nagy JM. Proteomics, nanotechnology and molecular 
diagnostics. Proteomics, 2008, 8(4):715-730 
20. Voduc D, Kenney C, Nielsen TO. Tissue microarrays in clinical oncology. Semin Radiat Oncol. 
2008, 18(2):89-97 
21. Hwang SI, Thumar J, Lundgren DH, Rezaul K, Mayya V, et al. Direct cancer tissue proteomics: a 
method to identify candidate cancer biomarkers from formalin-fixed paraffin-embedded archival 
tissues. Oncogene. 2007, 26(1):65 
22. Drev P, Grazio SF, & Bracko M. Tissue microarrays for routine diagnostic assessment of HER2 
status in breast carcinoma. Applied Immunohistochemistry & Molecular Morphology. 2008, 
16(2):179-184 
23. Hardouin J, Lasserre JP, Sylvius L, Joubert-Caron R, Caron M. Cancer immunomics: from 
serological proteome analysis to multiple affinity protein profiling. Annals of the New York 
Academy of Sciences. 2007, 1107(1):223-230 
24. Shangguan D, Cao Z, Meng L, Mallikaratchy P, Sefah K, et al. Cell-specific aptamer probes for 
membrane protein elucidation in cancer cells. Journal of proteome research. 2008, 
7(5):2133-2139 
25. Kopf, E., & Zharhary, D. Antibody arrays—an emerging tool in cancer proteomics. The 
international journal of biochemistry & cell biology. 2007, 39(7-8):1305-1317 
26. Nettikadan S, Radke K, Johnson J, Xu J, Lynch M, et al. Detection and quantification of protein 
biomarkers from fewer than 10 cells. Molecular & Cellular Proteomics. 2006, 5(5):895-901 
27. Pritchard KI, Shepherd LE, O'malley FP, Andrulis IL, Tu D, Bramwell VH, & Levine MN. HER2 
and responsiveness of breast cancer to adjuvant chemotherapy. New England Journal of Medicine. 
2006, 354(20):2103-2111 
28. Carney WP, Leitzel K, Ali S, Neumann R, & Lipton A. HER-2 therapy. HER-2/neu diagnostics in 
breast cancer. Breast Cancer Research. 2007, 9(3):207 
29. Lin JF, Xu J, Tian HY, Gao X, Chen QX, et al. Identification of candidate prostate cancer 
biomarkers in prostate needle biopsy specimens using proteomic analysis. International journal of 
cancer. 2007, 121(12):2596-2605 
  
 
Ivy Union Publishing | http: //www.ivyunion.org            ISSN 2572-5750           January 22, 2019 | Volume 7 | Issue 1 
Nimbalkar CK. American Journals of Cancer Science 2019, 7:1-17                                     Page 15 of 17 
 
7 
6 
30. Conrad DH, Goyette J, & Thomas PS. Proteomics as a method for early detection of cancer: a 
review of proteomics, exhaled breath condensate, and lung cancer screening. Journal of General 
Internal Medicine. 2008, 23(1):78-84 
31. Patz Jr EF, Campa MJ, Gottlin EB, Kusmartseva I, Guan XR, & Herndon JE. Panel of serum 
biomarkers for the diagnosis of lung cancer. Journal of Clinical Oncology. 
2007, 25(35):5578-5583 
32. D’Amico TA. Molecular biologic staging of lung cancer. The Annals of thoracic surgery. 2008, 
85(2):S737-S742 
33. López‐Pedrera C, Villalba JM, Siendones E, Barbarroja N, Gómez‐Díaz C, et al. Proteomic 
analysis of acute myeloid leukemia: Identification of potential early biomarkers and therapeutic 
targets. Proteomics. 2006, 6(S1):S293-S299 
34. Gjertsen BT, & Sjøholt G. Proteomic Strategies of Therapeutic Individualization and Target 
Discovery in Acute Myeloid Leukemia. Cancer Proteomics. 2008, 161-187 
35. Habermann JK, Bader FG, Franke C, Zimmermann K, Gemoll T, et al. From the genome to the 
proteome—biomarkers in colorectal cancer. Langenbeck's archives of surgery. 
2008, 393(1):93-104 
36. Engwegen JY, Helgason HH, Cats A, Harris N, Bonfrer JM, et al. Identification of serum proteins 
discriminating colorectal cancer patients and healthy controls using surface-enhanced laser 
desorption ionisation-time of flight mass spectrometry. World journal of gastroenterology: 
WJG. 2006, 12(10):1536 
37. Zhao L, Liu L, Wang S, Zhang YF, Yu L, et al. Differential proteomic analysis of human colorectal 
carcinoma cell lines metastasis-associated proteins. Journal of cancer research and clinical 
oncology. 2007, 133(10):771-782 
38. Jain KK. Proteomics-based anticancer drug discovery. In: LaRochelle WJ. (Ed.), the 
Oncogenomics Handbook. The Humana Press, Totowa, New Jersey, 2005, pp. 123-134 
39. Jain KK. Proteomics-based anticancer drug discovery and development. Technology in cancer 
research & treatment. 2002, 1(4):231-236 
40. Hu S, Yen Y, Ann D, & Wong DT. Implications of salivary proteomics in drug discovery and 
development: a focus on cancer drug discovery. Drug discovery today. 2007, 12(21-22):911-916 
41. Yazidi-Belkoura IE, Adriaenssens E, Vercoutter-Edouart AS, Lemoine J, Nurcombe V, et al. 
Proteomics of breast cancer: outcomes and prospects. Technology in cancer research & 
treatment. 2002, 1(4):287-295 
42. Steinert R, Buschmann T, Van der Linden M, Fels LM, Lippert H, et al. The role of proteomics in 
the diagnosis and outcome prediction in colorectal cancer. Technology in cancer research & 
treatment. 2002, 1(4):297-303 
43. Krieg RC, Paweletz CP, Liotta LA, & Petricoin III EF. Clinical proteomics for cancer biomarker 
discovery and therapeutic targeting. Technology in cancer research & treatment. 
2002, 1(4):263-272 
44. Kovarova H, Halada P, Man P, Dzubak P, & Hajduch M. Application of proteomics in the search 
for novel proteins associated with the anti-cancer effect of the synthetic cyclin-dependent kinases 
inhibitor, bohemine. Technology in cancer research & treatment. 2002, 1(4):247-256 
45. Zhang JT, & Liu Y. Use of comparative proteomics to identify potential resistance mechanisms in 
cancer treatment. Cancer treatment reviews. 2007, 33(8):741-756 
46. Jain KK. Role of proteomics in diagnosis of cancer. Technology in cancer research & 
treatment, 2002, 1(4), 281-286 
  
 
Ivy Union Publishing | http: //www.ivyunion.org            ISSN 2572-5750           January 22, 2019 | Volume 7 | Issue 1 
Nimbalkar CK. American Journals of Cancer Science 2019, 7:1-17                                     Page 16 of 17 
 
7 
6 
47. Le Naour F, Brichory F, Beretta L, & Hanash SM. Identification of tumor-associated antigens using 
proteomics. Technology in cancer research & treatment. 2002, 1(4):257-262 
48. Kim HK, Park WS, Kang SH, Warda M, Kim N, et al. Mitochondrial alterations in human gastric 
carcinoma cell line. Am J Physiol Cell Physiol. 2007, 293:C761-C771 
49. Liu C, Shea N, Rucker S, Harvey L, Russo P, et al. Proteomic patterns for classification of ovarian 
cancer and CTCL serum samples utilizing peak pairs indicative of post‐translational 
modifications. Proteomics. 2007, 7(22):4045-4052 
50. Helleman J, Van Der VLIES D, Jansen MPHM, Luider TM, Van Der BURG MEL, et al. Serum 
proteomic patterns for ovarian cancer monitoring. International Journal of Gynecological Cancer. 
2008, 18(5):985-995 
51. Ebert MP, Korc M, Malfertheiner P, & Röcken C. Advances, challenges, and limitations in 
serum-proteome-based cancer diagnosis. Journal of proteome research. 2006, 5(1):19-25 
52. Schippinger W, Dandachi N, Regitnig P, Hofmann G, Balic M, et al. The predictive value of EGFR 
and HER-2/neu in tumor tissue and serum for response to anthracycline-based neoadjuvant 
chemotherapy of breast cancer. American journal of clinical pathology. 2007, 128(4):630-637 
53. Goufman EI, Moshkovskii SA, Tikhonova OV, Lokhov PG, Zgoda VG, et al. Two-dimensional 
electrophoretic proteome study of serum thermostable fraction from patients with various tumor 
conditions. Biochemistry (Moscow). 2006, 71(4):354-360 
54. Kurebayashi J, Biomarkers in breast cancer. Gan to Kagaku Ryoho. 2004, 31:1021-1026 
55. Jain KK. Cancer biomarkers: current issues and future directions. Current opinion in molecular 
therapeutics. 2007, 9(6):563-571 
56. Adam BL, Qu Y, Davis JW, Ward MD, Clements MA, et al. Serum protein fingerprinting coupled 
with a pattern-matching algorithm distinguishes prostate cancer from benign prostate hyperplasia 
and healthy men. Cancer research. 2002, 62(13):3609-3614 
57. Zhang Z, Bast RC, Yu Y, Li J, Sokoll LJ, et al. Three biomarkers identified from serum proteomic 
analysis for the detection of early-stage ovarian cancer. Cancer research. 2004, 64(16):5882-5890 
58. Ward DG, Cheng Y, N'kontchou G, Thar TT, Barget N, et al. Changes in the serum proteome 
associated with the development of hepatocellular carcinoma in hepatitis C-related 
cirrhosis. British journal of cancer. 2006, 94(2):287 
59. Chen YD, Zheng S, Yu JK, & Hu X. Artificial neural networks analysis of surface-enhanced laser 
desorption/ionization mass spectra of serum protein pattern distinguishes colorectal cancer from 
healthy population. Clinical Cancer Research. 2004, 10(24):8380-8385 
60. Mueller J, Von Eggeling F, Driesch D, Schubert J, et al. ProteinChip technology reveals distinctive 
protein expression profiles in the urine of bladder cancer patients. European urology. 
2005, 47(6):885-894. 
61. Li J, Zhang Z, Rosenzweig J, Wang YY, & Chan DW. Proteomics and bioinformatics approaches 
for identification of serum biomarkers to detect breast cancer. Clinical chemistry. 2002, 
48(8):1296-1304. 
62. Poon TC, Sung JJ, Chow SM, Ng EK, et al. Diagnosis of gastric cancer by serum proteomic 
fingerprinting. Gastroenterology. 2006, 130(6):1858-1864 
63. Yang SY, Xiao XY, Zhang WG, Zhang LJ, et al. Application of serum SELDI proteomic patterns 
in diagnosis of lung cancer. BMC cancer. 2005, 5(1):83 
64. Koopmann J, Zhang Z, White N, Rosenzweig J, Fedarko N, et al. Serum diagnosis of pancreatic 
adenocarcinoma using surface-enhanced laser desorption and ionization mass 
spectrometry. Clinical Cancer Research. 2004, 10(3):860-868 
  
 
Ivy Union Publishing | http: //www.ivyunion.org            ISSN 2572-5750           January 22, 2019 | Volume 7 | Issue 1 
Nimbalkar CK. American Journals of Cancer Science 2019, 7:1-17                                     Page 17 of 17 
 
7 
6 
65. Jain KK. Oncoproteomics for personalized management of cancer. In Cancer Proteomics 
2008, (pp. 81-99). Humana Press 
66. Jain KK, Proteomics: Technologies, Markets and Companies. Jain PharmaBiotech Publications, 
Basel, Switzerland, 2008, pp. 1-570 
67. Espina V, Wulfkuhle J, Calvert VS, Liotta LA, & Petricoin EF. Reverse phase protein microarrays 
for theranostics and patient-tailored therapy. In Tissue Proteomics 2008, (pp. 113-128). Humana 
Press 
68. Veenstra TD. Where are all the biomarkers? Expert review of proteomics. 2011, 8(6), 681-683 
69. Veenstra TD. Proteomics research in breast cancer: balancing discovery and hypothesis-driven 
studies. Expert review of proteomics. 2011, 8(2):139-141 
70. Kočevar N, Hudler P, & Komel R. The progress of proteomic approaches in searching for cancer 
biomarkers. New biotechnology. 2013, 30(3):319-326 
71. Ray S, Reddy PJ, Jain R, Gollapalli K, Moiyadi A, et al. Proteomic technologies for the 
identification of disease biomarkers in serum: advances and challenges ahead. Proteomics. 
2011, 11(11):2139-2161 
 
 
 
